Trial Profile
A Phase-I Study of Nivolumab in Association With Radiotherapy and Cisplatin in Locally Advanced Cervical Cancers Followed by Adjuvant Nivolumab for up to 6 Months. NiCOL
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 05 Jul 2022
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Cisplatin
- Indications Adenocarcinoma; Cervical cancer; Squamous cell cancer
- Focus Adverse reactions
- Acronyms NiCOL
- 07 Jun 2022 Results (n=16) presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 28 Apr 2022 Status changed from active, no longer recruiting to completed.
- 05 Oct 2020 Planned End Date changed from 1 May 2022 to 15 Sep 2022.